CanSino Biologics Inc. (SHA:688185)
China · Delayed Price · Currency is CNY 66.20
+3.40 (5.41%)
Jul 17, 2025, 3:00 PM CST
CanSino Biologics Employees
CanSino Biologics had 1,105 employees as of December 31, 2024. The number of employees decreased by 389 or -26.04% compared to the previous year.
Employees
1,105
Change (1Y)
-389
Growth (1Y)
-26.04%
Revenue / Employee
786.62K CNY
Profits / Employee
-199.40K CNY
Market Cap
12.32B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,105 | -389 | -26.04% |
| Dec 31, 2023 | 1,494 | -797 | -34.79% |
| Dec 31, 2022 | 2,291 | 345 | 17.73% |
| Dec 31, 2021 | 1,946 | 1,602 | 465.70% |
| Dec 31, 2018 | 344 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jiangsu Hengrui Medicine | 20,238 |
| Shenzhen Mindray Bio-Medical Electronics | 21,667 |
| WuXi AppTec | 39,414 |
| Sichuan Biokin Pharmaceutical | 2,521 |
| Zhangzhou Pientzehuang Pharmaceutical., | 2,839 |
| Aier Eye Hospital Group | 42,693 |
| Shanghai United Imaging Healthcare | 8,173 |
| Yunnan Baiyao Group Co.,Ltd | 9,277 |
CanSino Biologics News
- 2 months ago - CanSino Biologics CEO on earnings, business outlook, and international partnerships - CNBC
- 2 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 2 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 3 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 3 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 3 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 3 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 3 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire